[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 27, 2004

Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292(16):1952-1953. doi:10.1001/jama.292.16.1952-a

To the Editor: We are concerned that the recent studies on enoxaparin vs unfractionated heparin leave the duration of heparin treatment ill-defined for patients with acute coronary syndromes.

In the SYNERGY trial,1 duration of drug administration was left to the judgment of the treating physician. SYNERGY was an open-label trial, and subcutaneous enoxaparin is more convenient than intravenous unfractionated heparin, which could lead to longer treatment. Therefore, it is possible that differences between enoxaparin and unfractionated heparin may be biased by longer treatment with 1 study drug. SYNERGY did not present actual duration of treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×